Heron Therapeutics Q3 net loss narrows to $41.9M; APONVIE approved, launch Q1 2023

HERON THERAPEUTICS, INC. /DE/

2022-Q3 EPS reported -$1.54 revenue$77,644,000

Net product sales $26.6M (+15% YoY); net loss $41.9M vs $52.4M YoY; oncology franchise sales $23.9M (+13%).
ZYNRELEF unit demand grew 18% QoQ; Q4 net sales expected to rise 30-40% QoQ.
APONVIE (aprepitant) FDA approved Sep 16; U.S. launch planned Q1 2023.
Completed $75M private placement to strengthen balance sheet; cash $121.7M.
Full-year 2022 oncology care franchise guidance reaffirmed at $93-95M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HERON THERAPEUTICS, INC. /DE/ reported three and nine months ended September 30, 2022 results: revenue $26.6 million and $77.6 million, net income $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share. Guidance reaffirmed.

Period: three and nine months ended September 30, 2022
Revenue: $26.6 million and $77.6 million
Net income: $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

franchises and extend our runway against a challenging external backdrop.” Financial Results Net product sales for the three and nine months ended September 30, 2022 were $26.6 million and $77.6 million, respectively, compared to $23.2 million and $65.7 million, respectively, for the same periods in 2021. Heron’s net loss for the three and nine months ended

View on SEC.gov

Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0001564590-22-037038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.